--- title: "Tevogen Advances Strategic Acquisition Plans With Potential To Add $100 Million In Annual Revenue" type: "News" locale: "en" url: "https://longbridge.com/en/news/288015400.md" description: "Tevogen Bio Holdings Inc. (TVGN) is advancing strategic acquisition plans that could add approximately $100 million in annual revenue. The company is evaluating the acquisition of a contract research organization and aims to expand into a three-pillar structure: biotechnology, technology, and healthcare services. CEO Ryan Saadi emphasized capital discipline in acquisitions. Following the announcement, shares rose 11.82% to $8.04, with overnight trading at $8.55, up 6.34%. Tevogen focuses on affordability and scientific rigor in healthcare." datetime: "2026-05-29T05:35:35.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/288015400.md) - [en](https://longbridge.com/en/news/288015400.md) - [zh-HK](https://longbridge.com/zh-HK/news/288015400.md) generator: "portal-rs" --- # Tevogen Advances Strategic Acquisition Plans With Potential To Add $100 Million In Annual Revenue (RTTNews) - Tevogen Bio Holdings Inc. (TVGN) announced continued progress on a series of strategic acquisition initiatives that the company says could collectively support approximately $100 million in combined annual revenue, if completed. Shares of the company moved higher following the update. The company noted that it is evaluating the acquisition of a contract research organization (CRO), along with additional opportunities aligned with its broader healthcare platform. These initiatives are intended to complement Tevogen's existing business and support its long-term goal of becoming a financially self-sustaining healthcare enterprise. Tevogen said the potential transactions could help expand the company into a three-pillar structure: Tevogen Bio (biotechnology), Tevogen.AI (technology), and a future healthcare services arm that may include management service and contract research operations. Founder and CEO Ryan Saadi, MD, MPH, emphasized that capital discipline remains a core priority, stating that any acquisition will be guided by strategic fit, long-term value creation, and responsible stewardship of the company's capital structure. He added that the goal is to build a healthcare enterprise with the financial strength to support operations, advance growth initiatives, and generate sustainable revenue. Tevogen describes itself as a socially integrated healthcare enterprise focused on affordability, efficiency, and scientific rigor. Its biotechnology arm, Tevogen Bio, has completed a proof-of-concept clinical trial demonstrating the potential of its single HLA-restricted, genetically unmodified allogeneic T-cell therapy, built on its proprietary ExacTcell platform. The company's pipeline spans virology, oncology, and neurology. The company recently implemented a 1-for-50 reverse stock split on March 2, 2026. TVGN closed Thursday's trading at $8.04, up 11.82%. During overnight trading the stock is at $8.55, up 6.34%. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. ### Related Stocks - [TVGNW.US](https://longbridge.com/en/quote/TVGNW.US.md) - [TVGN.US](https://longbridge.com/en/quote/TVGN.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [NDAQ.US](https://longbridge.com/en/quote/NDAQ.US.md) ## Related News & Research - [“We’re not doing 30 bets a year”: Vijay Pande on betting small after running $4 billion at a16z](https://longbridge.com/en/news/297407072.md) - [Tevogen Announces Formation of a Healthcare Services Initiative | TVGN Stock News](https://longbridge.com/en/news/289229521.md) - [Koala trial doses first patient with novel KMA‑targeting CAR‑T](https://longbridge.com/en/news/298021066.md) - [Grupa Azoty announces extraordinary shareholder meeting](https://longbridge.com/en/news/297635728.md) - [Tevogen Bio Shareholders Approve Governance-Enhancing Charter Changes](https://longbridge.com/en/news/297080768.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**